Pistoia Alliance October 13, 2015

Panel Topic: New Data

Panel Facilitator: Matthew Rich, Principle, PwCPanelists: • Joe Donahue, SVP, BioReference Labs• Niall O’Connor, CTO, Genospace• Nikolaus Schultz, AA Computational

Oncology Service, MSK CC

PwC

New Data:

We found data, now what do we do with it?

Copyright PwC 2015

Venture funding continues to pour into Analytics and Big Data, but the real story is that 5 of the top 6 categories are either sources or rely on Data…

Slide 3

Funding of Top Six 2014 Categories

Source: Rock Health Funding Database

Copyright PwC 2015

Funding for digital health, one key source of new data, continues to expand increasing in 2014 to a total greater than that of the past 3 years combined

Slide 4

Digital Health Funding in 2014 exceeded $4.1 billion, which represents a

growth of 124% over last year’s

investment total

Source: Rock Health Funding Database

Venture Capital Funding in Digital Health

$172 Million $135 Million $54 Million $36 Million $29 Million

Leading Digital Health Investments in 2015

*Digital health is defined as the intersection of healthcare and technology. Digital health venture funding tracked by Rock Health only includes technology-enabled health companies that build and sell technologies in medicine, wellness, or administration Source: Rock Health Funding Database

Copyright PwC 2015

With all of the “new” sources of data, what can we do…?

Slide 5

More than one million customers transmit data from fitness trackers to Walgreen Co., in exchange for points that can be used like cash in the company’s stores and through its website for many products.

By the end of 2014, wearable companies shipped ~7.6 million units within just the US, up 200% from 2013. This trend will continue.

Copyright PwC 2015

Answer: Listen to the three AMAZING panelists we have assembled today and

ask questions!!!

Slide 6

The Road to Customer-Centricity in Pharma R&D7Copyright PwC 2015

Appendix

March 2015

Copyright PwC 2015

PwC Perspective: Pharma must partner to realize the value of the vast amount of information available

Slide 8

Clinical Trials, and PipelineIdentifying high-value pipeline candidates to increase pipeline success, and expanding pipeline through licensing and acquisitions

Lab ResearchReducing R&D cycle time, costs and improving data

Clinical and Economic ValueDemonstrating drugs’ value in an outcome-based environment

Buyers and Distribution ChannelsRethinking the value chain as demand for services and products shift from traditional to NEI companies

Consumer EngagementConnecting with consumers throughout the entire life cycle of a drug

Innovation for product and

business operations

vs.

Copyright PwC 2015

Several startups are leveraging machine learning for unstructured data to improve patient outcomes

9

More unstructured data

More structured data

More focuson medicine (e.g., diagnosis, treatment)

Less focuson medicine (e.g., diagnosis, treatment)

Individual case data collection

Medical codingMedical recordsTraining data aggregation

Journal articlesTextbooks

Medical signals

Treatment plans

• Enlitic leverages the most significant untapped data sources within healthcare — medical signals and plain text

• Medical signal examples: medical images (CT, MRI, pathology, ultrasound, x-ray), EKG, genetics

Example